Nash Pharmaceuticals Announces Positive Pre-Clinical Results Showing Lead Compound NP-160 Significantly Reduces NALFD Score and Fibrosis in Non-Alcoholic Fatty Liver Disease

Planning Phase II Trial

VANCOUVER, BC – (November 1, 2018) – Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the "**Company**" or "Nash Pharma") is pleased to announce that its lead compound for non-alcoholic steatohepatitis ("NASH") NP-160 showed positive results in a recently completed study investigating its therapeutic effects in the widely used STAM™ mouse model from SMC Laboratories. NP-160 is one of a number of already approved compounds that Nash Pharma has been screening for new therapeutic uses as part of its drug repurposing strategy.

Data from this study demonstrated statistically significant improvements in several key measures relevant to the development and progression of NASH including:

- A 2.0 reduction in the NAFLD/NAS score vs controls ($p<0.05$)
- A 42.0% reduction in fibrosis as measured by Sirius red staining ($p<0.01$)
- In the same study, Telmisartan (a well accepted control in NASH studies) significantly reduced the NAS score by 2.0 points ($p<0.05$) and reduced fibrosis by 19.7% (not statistically significant)
- No negative side effects were observed.

"The NASH market segment represents an enormous unmet medical need globally and there is a particular interest in compounds exhibiting anti-fibrotic activity," said Christopher J. Moreau CEO of Nash Pharma. "We plan to present our preclinical *in vivo* NASH results at the upcoming 2nd Global NASH Congress, in February 2019 in London, UK and have now begun preparations to start a Phase IIa study for our repurposed lead candidate NP-160 in 2019."

About NASH/NFLD

According to a new report published by Allied Market Research, "Global Opportunity Analysis and Industry Forecast, 2021-2025," the global NASH market was valued at $1.17 Billion in 2017, and is expected to reach $21.4 Billion by 2025, growing at a CAGR of 58.4% from 2021 to 2025. Currently, there are no US FDA approved treatments for NAFLD or NASH.

About Nash Pharmaceuticals Inc.

Nash Pharmaceuticals Inc. is a wholly owned subsidiary of Breathtec Biomedical Inc. Nash is a clinical stage pharmaceutical development company focused on drug repurposing in the areas of non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) and inflammatory bowel disease (IBD). Drug repurposing is the process of discovering new therapeutic uses for existing drugs.

For more information, visit https://nashpharmaceuticals.com/.

CONTACT INFORMATION

Christopher J. Moreau
CEO
Nash Pharmaceuticals Inc.
604.398.4175 ext 701
info@breathtechbiomedical.com
investors@breathtecbiomedical.com
www.breathtecbiomedical.com

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.